

Study or Subgroup	SSRI		placebo		Weight	Risk Ratio		Risk Ratio	
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI		
29060/449 (A)	20	108	5	55	1.1%	2.04	[0.81, 5.14]		
29060/449 (B)	21	112	6	55	1.3%	1.72	[0.74, 4.01]		
29060/448 (A)	15	106	4	51	0.8%	1.80	[0.63, 5.16]		
29060/448 (B)	17	106	4	52	0.8%	2.08	[0.74, 5.88]		
29060/785 (A)	13	103	3	27	0.6%	1.14	[0.35, 3.70]		
29060/785 (B)	17	96	2	26	0.5%	2.30	[0.57, 9.52]		
29060/785 (C)	19	107	2	26	0.5%	2.31	[0.57, 9.29]		
29060/785 (D)	10	100	2	26	0.4%	1.30	[0.30, 5.57]		
Bali et al (2014)	6	79	2	79	0.4%	3.00	[0.62, 14.41]		
Bose 2008	10	130	17	134	1.6%	0.61	[0.29, 1.27]		
Burke et al. (A) 2002	10	119	3	122	0.6%	3.42	[0.96, 12.11]		
Burke et al. (B) 2002	14	125	3	122	0.6%	4.55	[1.34, 15.45]		
Burke et al. (C) 2002	11	125	3	122	0.6%	3.58	[1.02, 12.52]		
Byerley et al. 1988	13	32	7	29	1.5%	1.68	[0.78, 3.63]		
Cassano et al. 1986	15	161	6	149	1.1%	2.31	[0.92, 5.81]		
Claghorn et al. 1996	3	47	5	46	0.5%	0.59	[0.15, 2.32]		
Cohn et al. 1985	11	54	4	58	0.8%	2.95	[1.00, 8.72]		
Cohn et al. 1991	9	40	5	40	0.9%	1.80	[0.66, 4.90]		
Coleman et al. 1999	20	115	8	121	1.5%	2.63	[1.21, 5.73]		
Coleman et al. 2001	15	154	10	152	1.5%	1.48	[0.69, 3.19]		
Corrigan et al. 2000	6	33	1	34	0.2%	6.18	[0.79, 48.60]		
Croft et al. 1999	21	118	5	119	1.0%	4.24	[1.65, 10.86]		
Dominguez et al. 1985	9	33	5	31	0.9%	1.69	[0.64, 4.49]		
Dubé et al. 2009	2	62	4	138	0.3%	1.11	[0.21, 5.92]		
Dunlop et al (A)	12	105	4	20	0.9%	0.57	[0.20, 1.59]		
Dunlop et al (B)	22	104	4	19	1.0%	1.00	[0.39, 2.59]		
Dunlop et al (C)	29	107	3	19	0.8%	1.72	[0.58, 5.07]		
Fabre et al. 1985	5	22	1	26	0.2%	5.91	[0.75, 46.96]		
Fabre et al. 1995	33	278	8	91	1.7%	1.35	[0.65, 2.82]		
Fabre et al. 1996	7	46	2	44	0.4%	3.35	[0.74, 15.25]		
Fava et al. (A) 1998	16	55	1	9	0.3%	2.62	[0.39, 17.39]		
Fava et al. (B) 1998	11	54	1	10	0.2%	2.04	[0.29, 14.07]		
Fava et al. 2005	5	47	6	43	0.7%	0.76	[0.25, 2.32]		
Feighner et al. 1989b	4	31	3	19	0.5%	0.82	[0.20, 3.26]		
Feighner et al. 1999	94	521	14	129	3.3%	1.66	[0.98, 2.82]		
Goldstein et al (2002)	3	33	5	70	0.5%	1.27	[0.32, 5.01]		
Goldstein et al. 2004	7	87	5	89	0.7%	1.43	[0.47, 4.34]		
Griebel et al. 2012 a	3	84	3	75	0.4%	0.89	[0.19, 4.29]		
Griebel et al. 2012 b	0	80	3	77	0.1%	0.14	[0.01, 2.62]		
Kasper (A) 2005	4	173	2	90	0.3%	1.04	[0.19, 5.57]		
Kasper (B) 2005	3	164	2	90	0.3%	0.82	[0.14, 4.84]		
Kasper et al. 1995	13	110	9	108	1.4%	1.42	[0.63, 3.18]		
Kasper et al. 2011	3	140	3	71	0.4%	0.51	[0.11, 2.45]		
Kranzler et al. (A) 2006	11	89	8	100	1.2%	1.54	[0.65, 3.67]		
Kranzler et al. (B) 2006	11	70	7	69	1.2%	1.55	[0.64, 3.76]		
Learned et al. 2012	7	166	8	156	0.9%	0.82	[0.31, 2.21]		
Lepola et al. (A) 2003	10	155	2	77	0.4%	2.48	[0.56, 11.06]		
Lepola et al. (B) 2003	7	160	1	77	0.2%	3.37	[0.42, 28.90]		
LVM-MD-06	5	79	1	93	0.2%	5.89	[0.70, 49.33]		
Lydvard et al. 1997	8	132	3	129	0.5%	2.61	[0.71, 9.61]		
Mao et al (2015)	4	19	0	18	0.1%	8.55	[0.49, 148.33]		
Muijen et al. 1988	4	26	1	28	0.2%	4.31	[0.51, 36.08]		
MY-1043/BRL-029060/115 (A)	57	284	9	59	2.2%	1.32	[0.69, 2.51]		
MY-1043/BRL-029060/115 (B)	60	289	9	59	2.2%	1.36	[0.72, 2.59]		
MY-1045/BRL-029060/1 (PAR128) (A)	73	357	11	70	2.7%	1.30	[0.73, 2.32]		
MY-1045/BRL-029060/1 (PAR128) (B)	76	351	12	70	3.0%	1.26	[0.73, 2.19]		
NCT00668625 (A)	19	322	3	109	0.6%	2.14	[0.65, 7.10]		
NCT00668625 (B)	34	324	4	109	0.9%	2.86	[1.04, 7.88]		
NCT01473361	12	282	8	281	1.2%	1.49	[0.62, 3.60]		
Nemeroff et al. 2007	15	104	14	102	2.0%	0.05	[0.53, 2.09]		
Nierenberg et al (2007)	21	274	9	137	1.6%	1.17	[0.55, 2.48]		
Olie et al. 1997	11	129	11	129	1.4%	1.00	[0.45, 2.22]		
PAR 29060.07.001	3	13	3	12	0.5%	0.92	[0.23, 3.72]		
Perahia et al (2006)	6	97	0	99	0.1%	13.27	[0.76, 232.31]		
Rapaport (A) 2008	14	164	6	89	1.1%	1.27	[0.50, 3.18]		
Rapaport (B) 2008	9	173	5	89	0.8%	0.93	[0.32, 2.68]		
Ratti et al. 2011	11	120	6	120	1.0%	1.83	[0.70, 4.80]		
Reimherr et al. 1990	26	149	16	150	2.7%	1.84	[0.92, 2.92]		
Rickels et al. 1992	9	55	6	56	1.0%	1.53	[0.58, 4.00]		
Roose 2004	3	87	5	87	0.5%	3.62	[0.15, 2.52]		
Schatzberg 2006	11	100	4	96	0.7%	2.84	[0.87, 8.01]		
Schneider 2003	35	371	23	376	3.5%	1.54	[0.93, 2.58]		
SCT-MD 02 (A) 2002	17	125	4	64	0.8%	2.18	[0.76, 6.20]		
SCT-MD 02 (B) 2002	14	123	4	63	0.8%	1.79	[0.62, 5.22]		
SCT-MD-13	10	132	17	135	1.6%	0.60	[0.29, 1.27]		
SCT-MD-26	16	154	9	155	1.5%	1.79	[0.82, 3.93]		
SCT-MD-27 (A)	20	136	7	67	1.4%	1.41	[0.63, 3.16]		
SCT-MD-27 (B)	15	138	8	68	1.4%	0.92	[0.41, 2.07]		
SCT-MD-35	6	138	2	135	0.4%	2.93	[0.60, 14.29]		
Sheehan et al. 2009	18	99	8	95	1.5%	2.16	[0.99, 4.73]		
Silverstone et al. 1999	30	121	12	119	2.4%	2.48	[1.32, 4.57]		
Smith et al. 1992	8	39	2	38	0.4%	3.90	[0.89, 17.18]		
Sramek et al. 1995	17	72	8	72	1.5%	2.13	[0.98, 4.61]		
Tollefson et al. 1995	61	335	42	336	6.9%	1.46	[1.01, 2.09]		
Wakelin 1986	3	32	2	14	0.3%	0.66	[0.12, 3.50]		
Walczak et al. 1996	61	400	24	200	4.7%	1.27	[0.82, 1.97]		
Wang et al 2014	23	156	22	155	3.1%	1.04	[0.60, 1.78]		
WELL AK130926	12	149	14	137	1.7%	0.79	[0.38, 1.64]		
WELL AK130927	16	138	7	141	1.2%	2.34	[0.98, 5.50]		
Total (95% CI)		11934		7956	100.0%	1.49	[1.35, 1.64]		
Total events		1500		592					
Heterogeneity: Tau ² = 0.00; Chi ² = 84.13, df = 88 (P = 0.60); I ² = 0%									
Test for overall effect: Z = 8.20 (P < 0.00001)									

